Pouponneau Pierre, Bringout Gaël, Martel Sylvain
NanoRobotics Laboratory, Department of Computer and Software Engineering and Institute of Biomedical Engineering, Ecole Polytechnique de Montréal (EPM), C.P. 6079, Succ. Centre-ville, Montreal, QC, H3C 3A7, Canada.
Ann Biomed Eng. 2014 May;42(5):929-39. doi: 10.1007/s10439-014-0972-1. Epub 2014 Jan 17.
This review paper describes the past, present and future design of therapeutic magnetic carriers (TMMC) being guided in the vascular network using a novel technique known as magnetic resonance navigation (MRN). This targeting method is an extension of magnetic resonance imaging (MRI) technologies. MRN, based on magnetic gradient variation, aims to navigate carriers in real-time along a pre-planned trajectory from their injection site to a targeted area. As such, this approach should minimize systemic distribution of toxic agents loaded into the carriers and improve therapeutic efficacy by delivering a larger proportion of the drug injected. MRN-compatible carriers (shape, material, size, magnetic properties, biocompatibility) have to be designed by taking into consideration the constraints of the medical task and MRN. In the past, as a proof of concept of MRN feasibility, a 1.5-mm ferromagnetic bead was guided in the artery of a living swine with a clinical MRI system. Present day, to aim at medical applications, TMMC have been designed for targeted liver chemoembolization by MRN. TMMC are 50-μm biodegradable microparticles loaded with iron-cobalt nanoparticles and doxorubicin as an antitumor drug. TMMC were selectively guided to the right or left liver lobes in a rabbit model with a clinical MRI scanner upgraded with steering coils. To treat human liver tumor, according to the theoretical MRN model, future TMMC design should take into consideration magnetic nanoparticle properties (nature and loading), MRN platform performances (gradient amplitude and rise time) and vascular hepatic network properties (blood flow velocity and geometry) to optimize the carrier diameter for efficient chemoembolization.
这篇综述论文描述了治疗性磁性载体(TMMC)过去、现在和未来的设计,该载体利用一种称为磁共振导航(MRN)的新技术在血管网络中进行引导。这种靶向方法是磁共振成像(MRI)技术的延伸。基于磁梯度变化的MRN旨在沿着预先规划的轨迹实时引导载体从注射部位到达目标区域。因此,这种方法应尽量减少载体中加载的有毒物质的全身分布,并通过输送更大比例的注射药物来提高治疗效果。必须考虑医学任务和MRN的限制来设计与MRN兼容的载体(形状、材料、尺寸、磁性、生物相容性)。过去,作为MRN可行性的概念验证,使用临床MRI系统在活猪的动脉中引导了一个1.5毫米的铁磁珠。如今,为了实现医学应用,已设计出通过MRN进行靶向肝脏化疗栓塞的TMMC。TMMC是50微米的可生物降解微粒,负载有铁钴纳米颗粒和作为抗肿瘤药物的阿霉素。在配备了转向线圈的临床MRI扫描仪的兔模型中,TMMC被选择性地引导至右肝叶或左肝叶。为了治疗人类肝脏肿瘤,根据理论MRN模型,未来TMMC的设计应考虑磁性纳米颗粒的特性(性质和负载量)、MRN平台性能(梯度幅度和上升时间)以及肝血管网络特性(血流速度和几何形状),以优化载体直径以实现高效的化疗栓塞。